BUILDING A BUSINESS FROM THE GROUND UP ISN'T AN EASY TASK,...

BUILDING A BUSINESS FROM THE GROUND UP ISN'T AN EASY TASK, EXPANDING AND GROWING IS A BALANCING ACT.

* TGA & EU approvals could take longer than anticipated, not to mention staff for the expanding jurisdictions.

* Product lines and approvals need funding as a move to the NASDAQ would too.

* ADMEDUS has secured a strategic investor that has released the security put down in the PFG loan by giving ADMEDUS an unsecured loan for 5M and to help ADMEDUS by taking shares instead of cash for the quarterly repayments. ADMEDUS's cash burn would recede by approximately 600K per QTR not to mention Star Bright will set up an office in the Peoples Republic of China to help ADMEDUS's expansion.

* The real question is where do I stand as a SH? Well Star Bright ended up with 20% of ADMEDUS which in turn gives Star Bright 20% more shares in ADMEDUS immunotherapies, meaning that Star Bright's percentage in AI is more like 68% and the rest of ADMEDUS (80% of SH's) own 24% of AI.

BEFORE

Star Bright - 60%

University - 10%

ADMEDUS - 30%

AFTER

Star Bright - 68%

University- 8%

ADMEDUS - 24%

* WP must bring another big player to the table to enhance others to join in and buy on market. This would make ADMEDUS's shares as rare as hen's teeth like the situation in AI.

* ASICS law allows Star Bright to accumulate 5% of ADMEDUS shares every 6 months which in turn gives SH's in ADMEDUS time for the quarterly results to improve exponentially.